Evaluating and treating small cell lung cancer

SCLC accounts for less than 15% of newly diagnosed lung cancers and can be distinguished from NSCLC by a high cell turnover rate and a rapidly progressive disease course, with a median survival of 3 months without treatment in extensive disease